AMARIN CORP PLC\UK Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for the quarter ending 2019-09-30 was $440.11M.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for the quarter ending 2018-12-31 was $194.83M.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for the quarter ending 2018-09-30 was $0.00.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for the quarter ending 2018-06-30 was $0.00.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for fiscal 2019 was $440.11M, a 66.18% increase from fiscal 2018.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for fiscal 2018 was $264.84M.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for fiscal 2016 was $64.61M.
- AMARIN CORP PLC\UK stock issued during period, value, new issues for fiscal 2013 was $121.21M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2019-12-31 | $440.11M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $440.11M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $194.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $264.84M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | |
| 2018-03-31 | $70.01M 10-Q · filed 2019-11-05 | |
| 2016-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $64.61M 10-K · filed 2019-02-27 |
| 2015-09-30 | $5.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | |
| 2015-06-30 | -$104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | |
| 2015-03-31 | $52.25M 10-Q · filed 2015-05-08 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $121.21M 10-K · filed 2016-02-25 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $98.65M 10-K · filed 2013-02-28 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | |
| 2011-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | |
| 2011-03-31 | $98.67M 10-Q · filed 2012-05-08 | |
| 2009-12-31 | $62.25M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |